Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease

被引:31
|
作者
Nobbio, L
Vigo, T
Abbruzzese, M
Levi, G
Brancolini, C
Mantero, S
Grandis, M
Benedetti, L
Mancardi, G
Schenone, A
机构
[1] Univ Genoa, Dept Neurosci Ophthalmol & Genet, I-16132 Genoa, Italy
[2] Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy
[3] MNHN, CNRS, UMR8572, F-75005 Paris, France
[4] Univ Udine, Dept Biomed Sci & Technol, Biol Sect, I-33100 Udine, Italy
[5] Dulbecco Telethon Inst, CNR, ITB, I-20090 Segrate, Italy
关键词
CMTlA; hereditary neuropathy; PMP22; Schwann cell; axon; motility; migration; proliferation; myelin; dysmyelination;
D O I
10.1016/j.nbd.2004.02.007
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Charcot-Marie-Tooth type 1A (CMT1A) is a hereditary demyelinating neuropathy due to an increased genetic dosage of the peripheral myelin protein 22 (PMP22). The mechanisms leading from PMP22 overexpression to impairment of myelination are still unclear. We evaluated expression and processing of PMP22, viability, proliferation, migration, motility and shaping properties, and ability of forming myelin of PMP22 transgenic (PMP22(tg)) Schwann cells in culture. In basal conditions, PMP22(tg) Schwann cells, although expressing higher PMP22 levels than control ones, show normal motility, migration and shaping properties. Addition of forskolin to the media induces an additional stimulation of PMP22 expression and results in an impairment of cells migration and motility, and a reduction of cell area and perimeter. Similarly, co-culturing transgenic Schwann cells with neurons causes an altered cells differentiation and an impairment of myelin formation. In conclusion, exposure of PMP22tg Schwann to the axon or to axonal-mimicking stimuli significantly affects the transition of transgenic Schwann cells to the myelinating phenotype. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:263 / 273
页数:11
相关论文
共 50 条
  • [21] CHARCOT-MARIE-TOOTH DISEASE TYPE 1A - MORPHOLOGICAL PHENOTYPE OF THE 17P DUPLICATION VERSUS PMP22 POINT MUTATIONS
    GABREELSFESTEN, AAWM
    BOLHUIS, PA
    HOOGENDIJK, JE
    VALENTIJN, LJ
    ESHUIS, EJHM
    GABREELS, FJM
    ACTA NEUROPATHOLOGICA, 1995, 90 (06) : 645 - 649
  • [22] NEW PERIPHERAL MYELIN PROTEIN 22 (PMP22) TRANSCRIPTIONAL VARIANTS IN CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) NEUROPATHY
    Visigalli, D.
    Fiorina, E.
    Mancardi, G. L.
    Santoro, L.
    Pareyson, D.
    Schenone, A.
    Nobbio, L.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2011, 16 : S144 - S145
  • [23] Post-transcriptional microRNA repression of PMP22 dose in severe Charcot-Marie-Tooth disease type 1
    Pipis, Menelaos
    Won, Seongsik
    Poh, Roy
    Efthymiou, Stephanie
    Polke, James M.
    Skorupinska, Mariola
    Blake, Julian
    Rossor, Alexander M.
    Moran, John J.
    Munot, Pinki
    Muntoni, Francesco
    Laura, Matilde
    Svaren, John
    Reilly, Mary M.
    BRAIN, 2023, 146 (10) : 4025 - 4032
  • [24] Comparison between Clinical Disabilities and Electrophysiological Values in Charcot-Marie-Tooth 1A Patients with PMP22 Duplication
    Kim, Young Hwa
    Chung, Hwa Kyung
    Park, Kee Duk
    Choi, Kyoung-Gyu
    Kim, Seung-Min
    Sunwoo, Il-Nam
    Choi, Young-Chul
    Lim, Jeong-Geun
    Lee, Kwang Woo
    Kim, Kwang-Kuk
    Lee, Dong Kuk
    Joo, In Soo
    Kwon, Ki-Han
    Gwon, Seok Beom
    Park, Jae Hyeon
    Kim, Dae-Seong
    Kim, Seung Hyun
    Kim, Woo-Kyung
    Suh, Bum Chun
    Kim, Sang-Beom
    Kim, Nam-Hee
    Sohn, Eun Hee
    Kim, Ok-Joon
    Kim, Hyun Sook
    Cho, Jung Hee
    Kang, Sa-Yoon
    Park, Chan-Ik
    Oh, Jiyoung
    Shin, Jong Hyu
    Chung, Ki Wha
    Choi, Byung-Ok
    JOURNAL OF CLINICAL NEUROLOGY, 2012, 8 (02): : 139 - 145
  • [25] PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker
    Nobbio, Lucilla
    Visigalli, Davide
    Radice, Davide
    Fiorina, Elisabetta
    Solari, Alessandra
    Lauria, Giuseppe
    Reilly, Mary M.
    Santoro, Lucio
    Schenone, Angelo
    Pareyson, Davide
    BRAIN, 2014, 137 : 1614 - 1620
  • [26] Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A
    Suzan Boutary
    Marie Caillaud
    Mévidette El Madani
    Jean-Michel Vallat
    Julien Loisel-Duwattez
    Alice Rouyer
    Laurence Richard
    Céline Gracia
    Giorgia Urbinati
    Didier Desmaële
    Andoni Echaniz-Laguna
    David Adams
    Patrick Couvreur
    Michael Schumacher
    Charbel Massaad
    Liliane Massaad-Massade
    Communications Biology, 4
  • [27] Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A
    Boutary, Suzan
    Caillaud, Marie
    El Madani, Mevidette
    Vallat, Jean-Michel
    Loisel-Duwattez, Julien
    Rouyer, Alice
    Richard, Laurence
    Gracia, Celine
    Urbinati, Giorgia
    Desmaele, Didier
    Echaniz-Laguna, Andoni
    Adams, David
    Couvreur, Patrick
    Schumacher, Michael
    Massaad, Charbel
    Massaad-Massade, Liliane
    COMMUNICATIONS BIOLOGY, 2021, 4 (01)
  • [28] DUPLICATION OF THE PMP22 GENE IN 17P PARTIAL TRISOMY PATIENTS WITH CHARCOT-MARIE-TOOTH TYPE 1A NEUROPATHY
    ROA, BB
    GREENBERG, F
    GUNARATNE, P
    SAUER, CM
    LUBINSKY, MS
    KOZMA, C
    MECK, JM
    MAGENIS, RE
    SHAFFER, LG
    LUPSKI, JR
    AMERICAN JOURNAL OF HUMAN GENETICS, 1995, 57 (04) : 171 - 171
  • [29] PMP22 immunoreactivity on biopsied sural nerves in Charcot-Marie-Tooth disease 1A and hereditary neuropathy with liability to pressure palsies
    Vallat, JM
    Sindou, P
    Preux, PM
    Tabaraud, F
    Couratier, P
    Milor, AM
    Brice, A
    LeGuern, E
    NEUROLOGY, 1996, 46 (02) : 35004 - 35004
  • [30] Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot-Marie-Tooth disease type 1A
    Sancho, S
    Young, P
    Suter, U
    BRAIN, 2001, 124 : 2177 - 2187